180 related articles for article (PubMed ID: 30446771)
1. Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry.
Lee YK; Byun DW; Jung SM; Kwon HY; Kim HY; Kim SH; Kim TY; Jang S; Ha YC
Calcif Tissue Int; 2019 Mar; 104(3):313-319. PubMed ID: 30446771
[TBL] [Abstract][Full Text] [Related]
2. Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort.
Won SH; Ahn S; Ji E; Park JW; Kim JK; Lee YK
J Korean Med Sci; 2020 Jun; 35(25):e193. PubMed ID: 32597040
[TBL] [Abstract][Full Text] [Related]
3. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
[TBL] [Abstract][Full Text] [Related]
4. Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population.
Cho YJ; Kang KC; Chun YS; Rhyu KH; Kim SJ; Jang TS
Arch Osteoporos; 2018 May; 13(1):53. PubMed ID: 29725835
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate use and subsequent hip fracture in South Korea.
Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
[TBL] [Abstract][Full Text] [Related]
6. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
7. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
8. Incidence of atypical nontraumatic diaphyseal fractures of the femur.
Dell RM; Adams AL; Greene DF; Funahashi TT; Silverman SL; Eisemon EO; Zhou H; Burchette RJ; Ott SM
J Bone Miner Res; 2012 Dec; 27(12):2544-50. PubMed ID: 22836783
[TBL] [Abstract][Full Text] [Related]
9. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.
Lee YK; Ahn S; Kim KM; Suh CS; Koo KH
J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947
[TBL] [Abstract][Full Text] [Related]
10. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.
Napoli N; Jin J; Peters K; Wustrack R; Burch S; Chau A; Cauley J; Ensrud K; Kelly M; Black DM
J Clin Endocrinol Metab; 2012 Jul; 97(7):2414-22. PubMed ID: 22547423
[TBL] [Abstract][Full Text] [Related]
11. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.
Sasaki S; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2012 Sep; 30(5):561-7. PubMed ID: 22610061
[TBL] [Abstract][Full Text] [Related]
12. Diaphyseal femur fractures associated with bisphosphonate use.
Graham J; Irgit K; Smith WR; Bowen TR
Acta Orthop Traumatol Turc; 2013; 47(4):255-60. PubMed ID: 23999513
[TBL] [Abstract][Full Text] [Related]
13. Increased risk for atypical fractures associated with bisphosphonate use.
Lee S; Yin RV; Hirpara H; Lee NC; Lee A; Llanos S; Phung OJ
Fam Pract; 2015 Jun; 32(3):276-81. PubMed ID: 25846215
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
15. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
17. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
Abrahamsen B; Eiken P; Eastell R
J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry.
Lee YK; Ha YC; Park C; Yoo JJ; Shin CS; Koo KH
Osteoporos Int; 2013 Feb; 24(2):707-11. PubMed ID: 22618268
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for fracture among current, persistent users of bisphosphonates.
LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
[TBL] [Abstract][Full Text] [Related]
20. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
